1. Hansen OP, Pedersen-Bjergaard J, Ellegaard J, Brincker H, Boesen AM, Christensen BE, Drivsholm Aa, Hippe E, Jans H, Jensen KB, Killmann S-Aa, Jensen MK, Karle H, Lauersen B, Nielsen JB, Nissen NI, Thorling K: Aclarubicin plus cytosine arbinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. Leukemia 5:510?516, 1991
2. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF: Adriamycin-induced DNA damage mediated by mamma-lian DNA topoisomerase II. Science 226:466?468, 1984
3. Ross W, Bradley MO: DNA double-strand breaks in mammalian cells after exposure to intercalating agents. Biochemica et Biophysica Acta 654:129?134, 1981
4. Jensen PB, Sørensen BS, Sehensted M, Demant EJF, Kjeldsen E, Friche E, Hansen HH: Different modes of anthracycline interaction with topoisomerase II: separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drag resistance. Biochem Pharmacol 45:2025?2035, 1993
5. Pedersen-Bjergaard J, Brincker H, Ellegaard J, Drivsholm A, Freund L, Jensen KB, Jensen MK, Nissen NI: Aclarubicin in the treatment of acute nonlymphocytic leukemia refractory to treatment with daunomycin and cytarabine: A phase II trial. Cancer Treatment Reports 68:1233?1238, 1984